drugset
drugset / Trial / NCT03196921

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection

NCT03196921 ↗

Phase 1/2 Withdrawn Matinas BioPharma Nanotechnologies, Inc. University of Minnesota · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This will be an open label phase I/II prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection.

Timeline

Start
2018-10-01
Primary completion
2019-10-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown — Oral

Indications

cryptococcosis